JY
DFTX

Jeff Yass’s Definium Therapeutics DFTX Stock Holding History

Jeff Yass’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.2M Buy
1,386,400
+546,400
+65% +$13.5M 0.01% 1294
2026
Q1 		$15.9M Buy
840,000
+256,400
+44% +$4.35M ﹤0.01% 2501
2025
Q4 		$7.81M Sell
583,600
-213,800
-27% -$2.65M ﹤0.01% 3376
2025
Q3 		$9.4M Buy
797,400
+459,200
+136% +$4.28M ﹤0.01% 3119
2025
Q2 		$2.19M Buy
338,200
+69,500
+26% +$457K ﹤0.01% 5604
2025
Q1 		$1.57M Buy
268,700
+194,600
+263% +$1.39M ﹤0.01% 6100
2024
Q4 		$516K Sell
74,100
-137,300
-65% -$945K ﹤0.01% 8589
2024
Q3 		$1.2M Sell
211,400
-368,300
-64% -$2.56M ﹤0.01% 6370
2024
Q2 		$4.18M Sell
579,700
-366,300
-39% -$3.2M ﹤0.01% 3736
2024
Q1 		$8.89M Sell
946,000
-165,700
-15% -$945K ﹤0.01% 2770
2023
Q4 		$4.07M Buy
1,111,700
+45,900
+4% +$138K ﹤0.01% 4068
2023
Q3 		$3.34M Buy
1,065,800
+104,000
+11% +$427K ﹤0.01% 4199
2023
Q2 		$3.43M Sell
961,800
-42,000
-4% -$145K ﹤0.01% 4146
2023
Q1 		$3.18M Sell
1,003,800
-862,200
-46% -$2.87M ﹤0.01% 4206
2022
Q4 		$4.11M Sell
1,866,000
-214,300
-10% -$595K ﹤0.01% 3537
2022
Q3 		$7.28M Buy
2,080,300
+1,997,220
+2,404% +$19.2M ﹤0.01% 2591
2022
Q2 		$798K Sell
83,080
-26,433
-24% -$334K ﹤0.01% 7076
2022
Q1 		$1.82M Buy
109,513
+45,346
+71% +$787K ﹤0.01% 5685
2021
Q4 		$1.33M Buy
64,167
+1,007
+2% +$32.1K ﹤0.01% 6513
2021
Q3 		$2.21M Buy
63,160
+21,480
+52% +$929K ﹤0.01% 5613
2021
Q2 		$2.16M Buy
+41,680
New +$2.19M ﹤0.01% 5745

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jeff Yass's DFTX Position: Q2 2026 in Review

Jeff Yass reduced its Definium Therapeutics (DFTX) stake by 50% in Q2 2026, selling an estimated $1M and leaving 40,954 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #6559.

Jeff Yass first reported a position in DFTX in Q2 2021 and has held it in 17 quarters since. The position peaked at $6.39M in Q4 2025. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Jeff Yass held 40,954 shares of Definium Therapeutics worth $1.93M as of Q2 2026.
  • Jeff Yass sold 40,502 Definium Therapeutics shares in Q2 2026, an estimated $1M.
  • Definium Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6559 holding.
  • Jeff Yass first reported a position in Definium Therapeutics in Q2 2021 and has held it in 17 quarters since.
  • Jeff Yass's Definium Therapeutics position peaked at $6.39M in Q4 2025.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.